Lucius LuciLeter Letermovir 240mg

Product Information

• Product name: LuciLeter Letermovir 240mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Letermovir
• Current strength: 240mg
• SKU: LU-ITEM-5
• Site category: other cancer

Product Summary

LuciLeter Letermovir 240mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Letermovir is the active ingredient used for this product page. Public prescribing information for Letermovir was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Letermovir is an antiviral drug against CMV .

Reference Indications

Letermovir is a CMV DNA terminase complex inhibitor indicated for: Prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). Prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).

Reference Dosage and Administration

Recommended dosage of Letermovir is 480 mg administered orally or intravenously once daily. administered once daily orally or as an intravenous (IV) infusion over 1 hour through 100 days post-HSCT.

With this 240mg product, that corresponds to 2 x 240mg tablets when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Consult the for contraindications and dosage recommendations for concomitant drugs. ( 4 , 5.1 , 7.1 , 7.2 , 7.3 ) Risks Associated with Hydroxypropyl Betadex Excipient in Intravenous Formulation: Intravenous formulation of Letermovir contains the excipient hydroxypropyl betadex. Letermovir injection should be used only in patients unable to take oral therapy. If possible, intravenous administration should not exceed 4 weeks. Animal studies have shown the potential for hydroxypropyl betadex to cause ototoxicity. Letermovir injection should be used only in patients unable to take oral therapy and patients should be switched to oral Letermovir as soon as they are able to take oral medications. If possible, intravenous administration should not exceed 4 weeks .

Common Adverse Reactions and Monitoring

Adult HSCT Patients: Most common adverse events (occurring in at least 10% of subjects in the Letermovir group and at a frequency at least 2% greater than placebo) are nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, and abdominal pain. Adult Kidney Transplant Patients: Most common adverse event (occurring in at least 10% of subjects in the Letermovir group and at a frequency greater than valganciclovir) is diarrhea. Pediatric Patients: Adverse events in pediatric patients are similar to adults.

Drug Interactions and Special Populations

Dosage Adjustment: If Letermovir is co-administered with cyclosporine, the dosage of Letermovir should be decreased to 240 mg once daily in adult and pediatric patients 12 years of age and older. If Letermovir is co-administered with cyclosporine in pediatric patients less than 12 years of age, dose adjustment may be required. Co-administration of Letermovir may alter the plasma concentrations of other drugs and other drugs may alter the plasma concentrations of Letermovir. ( 2.4 , 2.6 , 4 , 5.1 , 7.1 , 7.2 , 7.3 , 7.4 , 12.3 ) 7.1 Potential for Other Drugs to Affect Letermovir Letermovir is a substrate of organic anion-transporting polypeptide 1B1/3 (OATP1B1/3) and P-glycoprotein (P-gp) transporters and UDP-glucuronosyltransferase 1A1/3 (UGT1A1/3) enzymes.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: PREVYMIS public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.